{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:20:44Z","timestamp":1783592444623,"version":"3.55.0"},"reference-count":39,"publisher":"Bioscientifica","issue":"8","funder":[{"name":"National Science and Technology Council","award":["NSTC 112-2314-B-182A-111 -MY3"],"award-info":[{"award-number":["NSTC 112-2314-B-182A-111 -MY3"]}]},{"name":"New Taipei Municipal TuCheng Hospital","award":["CMRPVVM0062, CMRPVVN0131"],"award-info":[{"award-number":["CMRPVVM0062, CMRPVVN0131"]}]}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a serine\u2013threonine protein kinase that plays critical roles in cellular processes fundamental to cancer. DNA-PKcs may be a potential target for differentiated thyroid cancer (DTC) therapy. A DNA-PKcs inhibitor, M3814, was evaluated for its use in DTC therapy. M3814 caused cytotoxicity in a dose\u2013response fashion in four DTC cell lines (TPC1, K1, FTC-133, and FTC-238). M3814 induced cell cycle arrest at the S phase in DTC cells. M3814 monotherapy was able to repress the growth of the K1 tumor model. M3814 in combination with lenvatinib demonstrated synergism in vitro, and this combination was more effective than any single therapy in an FTC-133 xenograft model. These results reveal that M3814 has significant potential in treating DTC, singly or in drug combination.<\/jats:p>","DOI":"10.1530\/erc-25-0031","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T11:16:48Z","timestamp":1753096608000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["DNA-PKcs inhibition as a therapeutic approach for differentiated thyroid cancer"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8877-9685","authenticated-orcid":true,"given":"Shu-Fu","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation) 1 , ,","place":["New Taipei City, Taiwan"]},{"name":"College of Medicine, Chang Gung University 2 , ,","place":["Taoyuan, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Molecular Biology, National Yang Ming Chiao Tung University 3 , ,","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuen","family":"Hsueh","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University 2 , ,","place":["Taoyuan, Taiwan"]},{"name":"Department of Pathology, Chang Gung Memorial Hospital 4 , ,","place":["Taoyuan, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Chao","family":"Chou","sequence":"additional","affiliation":[{"name":"Laboratory of Preclinical Pharmacology Core, Memorial Sloan Kettering Cancer Center 5 , , ,","place":["New York, New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center 6 , , ,","place":["New York, New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"2026070905471888500_bib1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid cancer: a review","volume":"331","author":"Boucai","year":"2024","journal-title":"J Am Med Assoc"},{"key":"2026070905471888500_bib2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"2026070905471888500_bib3","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026070905471888500_bib4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1186\/s12935-021-02229-8","article-title":"Role of PRKDC in cancer initiation, progression, and treatment","volume":"21","author":"Chen","year":"2021","journal-title":"Cancer Cell Int"},{"key":"2026070905471888500_bib5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"2026070905471888500_bib6","volume-title":"Compusyn for Drug Combinations: PC Software and Users Guide: A Computer Program for Quantitation of Synergism and Antagonism in Drug Combinations and The Determination of IC50, ED50, and LD50 Values","author":"Chou","year":"2005"},{"key":"2026070905471888500_bib7","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1128\/MCB.25.24.10842-10852.2005","article-title":"Autophosphorylation of DNA-dependent protein kinase regulates DNA end processing and may also alter double-strand break repair pathway choice","volume":"25","author":"Cui","year":"2005","journal-title":"Mol Cell Biol"},{"key":"2026070905471888500_bib8","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905471888500_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/0008-5472.CAN-21-1756","article-title":"DNA-PKcs: a targetable protumorigenic protein kinase","volume":"82","author":"Dylgjeri","year":"2022","journal-title":"Cancer Res"},{"key":"2026070905471888500_bib10","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1038\/s41467-019-12836-9","article-title":"AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity","volume":"10","author":"Fok","year":"2019","journal-title":"Nat Commun"},{"key":"2026070905471888500_bib11","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/2159-8290.CD-14-0358","article-title":"Beyond DNA repair: DNA-PK function in cancer","volume":"4","author":"Goodwin","year":"2014","journal-title":"Cancer Discov"},{"key":"2026070905471888500_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ccell.2015.06.004","article-title":"DNA- PKcs-mediated transcriptional regulation drives prostate cancer progression and metastasis","volume":"28","author":"Goodwin","year":"2015","journal-title":"Cancer Cell"},{"key":"2026070905471888500_bib13","article-title":"Expanding the benefit: dabrafenib\/trametinib as tissue-agnostic therapy for BRAF V600E-positive adult and pediatric solid tumors","volume":"43","author":"Gouda","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026070905471888500_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"2026070905471888500_bib15","first-page":"22","article-title":"Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment","volume":"1","author":"Hsu","year":"2012","journal-title":"Transl Cancer Res"},{"key":"2026070905471888500_bib16","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.acthis.2016.05.002","article-title":"Ki67, PCNA, and MCM proteins: markers of proliferation in the diagnosis of breast cancer","volume":"118","author":"Jur\u00edkov\u00e1","year":"2016","journal-title":"Acta Histochem"},{"key":"2026070905471888500_bib17","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/SLA.0b013e318148563d","article-title":"The prevalence and prognostic value of BRAF mutation in thyroid cancer","volume":"246","author":"Kebebew","year":"2007","journal-title":"Ann Surg"},{"key":"2026070905471888500_bib18","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1001\/jama.2017.2719","article-title":"Trends in thyroid cancer incidence and mortality in the United States, 1974\u20132013","volume":"317","author":"Lim","year":"2017","journal-title":"J Am Med Assoc"},{"key":"2026070905471888500_bib19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1530\/ERC-18-0555","article-title":"Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer","volume":"26","author":"Lin","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2026070905471888500_bib20","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0142","article-title":"Therapeutic inhibition of ATR in differentiated thyroid cancer","volume":"30","author":"Lin","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"2026070905471888500_bib21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41467-018-03033-1","article-title":"Regulation of mutant TERT by BRAF V600E\/MAP kinase pathway through FOS\/GABP in human cancer","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"key":"2026070905471888500_bib22","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.3390\/cancers13143487","article-title":"Efficacy and biomarker analysis of adavosertib in differentiated thyroid cancer","volume":"13","author":"Lu","year":"2021","journal-title":"Cancers"},{"key":"2026070905471888500_bib23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3389\/fonc.2019.00635","article-title":"DNA-PK as an emerging therapeutic target in cancer","volume":"9","author":"Mohiuddin","year":"2019","journal-title":"Front Oncol"},{"key":"2026070905471888500_bib24","article-title":"Thyroid carcinoma. Version 4. Plymouth Meeting, PA, USA: National Comprehensive Cancer Network","author":"NCCN","year":"2024"},{"key":"2026070905471888500_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.860671","article-title":"Target therapy in thyroid cancer: current challenge in clinical use of tyrosine kinase inhibitors and management of side effects","volume":"13","author":"Puliafito","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026070905471888500_bib26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ijrobp.2023.09.024","article-title":"A phase 1 study of the DNA-PK inhibitor peposertib in combination with radiation therapy with or without cisplatin in patients with advanced head and neck tumors","volume":"118","author":"Samuels","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026070905471888500_bib27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070905471888500_bib28","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026070905471888500_bib29","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.trecan.2020.05.009","article-title":"Clinical development of BRAF plus MEK inhibitor combinations","volume":"6","author":"Subbiah","year":"2020","journal-title":"Trends Cancer"},{"key":"2026070905471888500_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1083\/jcb.200608077","article-title":"Autophosphorylation of DNA-PKCS regulates its dynamics at DNA double-strand breaks","volume":"177","author":"Uematsu","year":"2007","journal-title":"J Cell Biol"},{"key":"2026070905471888500_bib31","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41416-020-01151-6","article-title":"A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours","volume":"124","author":"van Bussel","year":"2021","journal-title":"Br J Cancer"},{"key":"2026070905471888500_bib32","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1016\/j.apsb.2021.07.029","article-title":"DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"2026070905471888500_bib33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1634\/theoncologist.2015-0107","article-title":"Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas","volume":"21","author":"Wassermann","year":"2016","journal-title":"Oncologist"},{"key":"2026070905471888500_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54796-6","article-title":"Activity of M3814, an oral DNA-PK inhibitor, in combination with topoisomerase II inhibitors in ovarian cancer models","volume":"9","author":"Wise","year":"2019","journal-title":"Sci Rep"},{"key":"2026070905471888500_bib35","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3389\/fonc.2020.00674","article-title":"M3814, a DNA-PK inhibitor, modulates ABCG2-mediated multidrug resistance in lung cancer cells","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"key":"2026070905471888500_bib36","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/jama.2013.3190","article-title":"Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer","volume":"309","author":"Xing","year":"2013","journal-title":"J Am Med Assoc"},{"key":"2026070905471888500_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.607428","article-title":"DNA-PKcs: a multi-faceted player in DNA damage response","volume":"11","author":"Yue","year":"2020","journal-title":"Front Genet"},{"key":"2026070905471888500_bib38","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1158\/1535-7163.MCT-19-0734","article-title":"Pharmacologic inhibitor of DNA-PK, M3814, potentiates radiotherapy and regresses human tumors in mouse models","volume":"19","author":"Zenke","year":"2020","journal-title":"Mol Cancer Therapeut"},{"key":"2026070905471888500_bib39","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbrc.2019.11.133","article-title":"Inhibition of DNA-PKcs activity resensitizes uveal melanoma cells to radio- and chemotherapy","volume":"522","author":"Zhang","year":"2020","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/8\/ERC-25-0031.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/8\/ERC-25-0031.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0031\/145478\/erc-25-0031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0031\/145478\/erc-25-0031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:47:28Z","timestamp":1783590448000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/8\/e250031\/26011\/DNA-PKcs-inhibition-as-a-therapeutic-approach-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0031","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"article-number":"e250031"}}